ProMIS Neurosciences Inc. reports clinical-stage biotechnology developments around antibody therapeutics and vaccines that target toxic misfolded proteins in neurodegenerative diseases. Company news centers on PMN310, its lead humanized monoclonal antibody for Alzheimer’s disease, the PRECISE-AD clinical program, FDA Fast Track designation, biomarker research involving plasma pTau, and scientific publications or conference presentations tied to Alzheimer’s disease, ALS, and Parkinson’s disease.
Updates also cover operating and financial results, governance matters, shareholder votes, capital-structure actions, and investor conference participation. The company’s research disclosures emphasize its proprietary discovery platform and selective targeting of disease-specific toxic protein species rather than broader amyloid plaque binding.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.